These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 33490708)

  • 1. Design and implementation of a prospective cohort study of persons living with and without HIV infection who are initiating medication treatment for opioid use disorder.
    Biondi BE; Mohanty S; Wyk BV; Montgomery RR; Shaw AC; Springer SA
    Contemp Clin Trials Commun; 2021 Mar; 21():100704. PubMed ID: 33490708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and implementation of a cohort study of persons living with HIV infection who are initiating medication treatment for opioid use disorder to evaluate HIV-1 persistence.
    Schultheis A; Sanchez M; Pedersen S; Kyriakides T; Ho YC; Kluger Y; Springer SA
    Contemp Clin Trials Commun; 2021 Dec; 24():100866. PubMed ID: 34825103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of intensity of behavioral treatment, with or without medication treatment, for opioid use disorder on HIV outcomes in persons with HIV.
    Kennedy AJ; McGinnis KA; Merlin JS; Edelman EJ; Gordon AJ; Korthuis PT; Skanderson M; Williams EC; Wyse J; Oldfield B; Bryant K; Justice A; Fiellin DA; Kraemer KL
    J Subst Abuse Treat; 2022 Jan; 132():108509. PubMed ID: 34130128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the Impact of HIV Serostatus on the Hepatitis C Virus Care Cascade and Injection Drug Use Among Persons Initiating Medication Treatment for Opioid Use Disorder.
    Lier AJ; Vander Wyk B; Di Paola A; Springer SA
    Open Forum Infect Dis; 2022 Nov; 9(11):ofac624. PubMed ID: 36467300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in Urine Drug Monitoring Among Persons Receiving Long-Term Opioids and Persons with Opioid Use Disorder in the United States.
    Sohn M; Talbert JC; Huang Z; Oser C; Freeman PR
    Pain Physician; 2021 Mar; 24(2):E249-E256. PubMed ID: 33740362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medications for opioid use disorder in pregnancy in a state women's prison facility.
    Knittel AK; Zarnick S; Thorp JM; Amos E; Jones HE
    Drug Alcohol Depend; 2020 Sep; 214():108159. PubMed ID: 32683223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioid use disorder incidence and treatment among incarcerated pregnant women in the United States: results from a national surveillance study.
    Sufrin C; Sutherland L; Beal L; Terplan M; Latkin C; Clarke JG
    Addiction; 2020 Nov; 115(11):2057-2065. PubMed ID: 32141128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of methamphetamine/amphetamine use on receipt and outcomes of medications for opioid use disorder: a systematic review.
    Frost MC; Lampert H; Tsui JI; Iles-Shih MD; Williams EC
    Addict Sci Clin Pract; 2021 Oct; 16(1):62. PubMed ID: 34635170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of a pharmacist-led substance use disorder transitions of care clinic on postdischarge medication treatment retention.
    Smith A; Hansen J; Colvard M
    J Subst Abuse Treat; 2021 Nov; 130():108440. PubMed ID: 34118708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrating long-acting injectable treatment to improve medication adherence among persons living with HIV and opioid use disorder: study protocol.
    Langdon KJ; Hitch AE; Collins AB; Beckwith CG; Becker S; Tashima K; Rich JD
    Addict Sci Clin Pract; 2023 Oct; 18(1):60. PubMed ID: 37838707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An ethical analysis of medication treatment for opioid use disorder (MOUD) for persons who are incarcerated.
    Brezel ER; Powell T; Fox AD
    Subst Abus; 2020; 41(2):150-154. PubMed ID: 31800376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans.
    Petrakis I; Springer SA; Davis C; Ralevski E; Gu L; Lew R; Hermos J; Nuite M; Gordon AJ; Kosten TR; Nunes EV; Rosenheck R; Saxon AJ; Swift R; Goldberg A; Ringer R; Ferguson R
    Addict Sci Clin Pract; 2022 Jan; 17(1):6. PubMed ID: 35101115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
    Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
    Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Systematic Review and Meta-Analysis of Studies Evaluating the Effect of Medication Treatment for Opioid Use Disorder on Infectious Disease Outcomes.
    McNamara KF; Biondi BE; Hernández-Ramírez RU; Taweh N; Grimshaw AA; Springer SA
    Open Forum Infect Dis; 2021 Aug; 8(8):ofab289. PubMed ID: 34430670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing Reasons for Starting and Stopping Methadone, Buprenorphine, and Naltrexone Treatment Among a Sample of White Individuals With Opioid Use Disorder.
    Randall-Kosich O; Andraka-Christou B; Totaram R; Alamo J; Nadig M
    J Addict Med; 2020; 14(4):e44-e52. PubMed ID: 31651562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cascade of care for opioid use disorder among youth in British Columbia, 2018.
    Krebs E; Min JE; Zhou H; Davison C; McGowan G; Nosyk B
    J Subst Abuse Treat; 2021 Nov; 130():108404. PubMed ID: 34118696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. College students' perceived knowledge of and perceived helpfulness of treatments for opioid use disorder at two American universities.
    Andraka-Christou B; Nguyen T; Harris S; Madeira J; Totaram R; Randall-Kosich O; Atkins D; Ford J
    Am J Drug Alcohol Abuse; 2020 Sep; 46(5):589-603. PubMed ID: 32543922
    [No Abstract]   [Full Text] [Related]  

  • 18. A Call to Action: Integration of Buprenorphine Prescribing Into the Care of Persons With Human Immunodeficiency Virus and Opioid Use Disorder.
    Fujita AW; Wilson JD; Kennedy AJ
    Open Forum Infect Dis; 2022 Aug; 9(8):ofac400. PubMed ID: 36039099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)".
    Shulman M; Weiss R; Rotrosen J; Novo P; Costello E; Nunes EV
    Addict Sci Clin Pract; 2021 Mar; 16(1):15. PubMed ID: 33676577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implications of Increased Access to Buprenorphine for Medical Providers in Rural Areas: A Review of the Literature and Future Directions.
    Gregory HM; Hill VM; Parker RW
    Cureus; 2021 Nov; 13(11):e19870. PubMed ID: 34976492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.